Cited by 135Alzheimer's disease research and treatmentsExtracellular vesicles in diseaseNanoparticle-Based Drug Delivery

Fe65-engineered neuronal exosomes encapsulating corynoxine-B ameliorate cognition and pathology of Alzheimer’s disease

Open access
Iyaswamy, Ashok, Thakur, Abhimanyu, Guan, Xin-Jie, Krishnamoorthi, Senthilkumar, Fung, Tsz Yan, Lu, Kejia, Gaurav, Isha, Yang, Zhijun +9 more·2023·Signal Transduction and Targeted Therapy

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the predominant impairment of neurons in the hippocampus and the formation of amyloid plaques, hyperphosphorylated tau protein, and neurofibrillary tangles in the brain. The overexpression of amyloid-β precursor protein (APP) in an AD brain results in the binding of APP intracellular domain (AICD) to Fe65 protein via the C-terminal Fe65-PTB2 interaction, which then triggers the secretion of amyloid-β and the consequent pathogenesis of AD. Apparently, targeting the interaction between APP and Fe65 can offer a promising therapeutic approach for AD. Recently, exosome, a type of extracellular vesicle with diameter around 30–200 nm, has gained much attention as a potential delivery tool for brain diseases, including AD, due to their ability to cross the blood–brain barrier, their efficient uptake by autologous cells, and their ability to be surface-modified with target-specific receptor ligands. Here, the engineering of hippocampus neuron cell-derived exosomes to overexpress Fe65, enabled the development of a novel exosome-based targeted drug delivery system, which carried Corynoxine-B (Cory-B, an autophagy inducer) to the APP overexpressed-neuron cells in the brain of AD mice. The Fe65-engineered HT22 hippocampus neuron cell-derived exosomes (Fe65-EXO) loaded with Cory-B (Fe65-EXO-Cory-B) hijacked the signaling and blocked the natural interaction between Fe65 and APP, enabling APP-targeted delivery of Cory-B. Notably, Fe65-EXO-Cory-B induced autophagy in APP-expressing neuronal cells, leading to amelioration of the cognitive decline and pathogenesis in AD mice, demonstrating the potential of Fe65-EXO-Cory-B as an effective therapeutic intervention for AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-023-01657-4

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Iyaswamy, A., Thakur, A., Guan, X.-J., Krishnamoorthi, S., Fung, T. Y., Lu, K., Gaurav, I., Yang, Z., Su, C.-F., Lau, K.-F., Zhang, K., Ng, R. C.-L., Lian, Q., Cheung, K.-H., Ye, K., Chen, H. J., & Li, M.
Affiliations
  • Hong Kong Baptist University (HK)
  • University of Chicago (US)
  • Chinese University of Hong Kong (HK)
  • Manchester Academic Health Science Centre (GB)
  • Guangzhou Women and Children Medical Center (CN)
  • Chinese Academy of Sciences (CN)
Corresponding author
  • Iyaswamy, Ashok
  • Thakur, Abhimanyu
  • Chen, Huanhuan Joyce
  • Li, Min
Venue
Signal Transduction and Targeted Therapy
Published
2023-10-23
Volume
8
Issue
1
Pages
404-404
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4387857159
Cited by
134
References
50
Citations by year
2026: 41 · 2025: 61 · 2024: 32
FWCI
23.80
Type
journal article
Language
en
Open access
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Research Explorer (The University of Manchester) (submittedVersion, cc-by)
  • University of Chicago (cc-by)
Funders
  • Cancer Research Foundation
  • Lung Cancer Research Foundation
  • University of Chicago
  • Hong Kong Baptist University (IRCMS/19–20/H02, RC-IRCS-17-18/03, HKBU/RC-IRCs/17-18/03, HKBU-MPCF-003-2022-23)
  • Health and Medical Research Fund (HMRF/17182551, 17182541, HMRF17182541, 17182551, 09203776)
  • National Cancer Institute (R00CA226353, K99CA226353)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
Alzheimer's disease, Fe65, amyloid precursor protein, exosome-based drug delivery, autophagy, hippocampal neurons, cognitive decline, amyloid plaques, tau hyperphosphorylation, extracellular vesicles
MeSH terms
Alzheimer Disease, Animals, Cognition, Indoles, Nerve Tissue Proteins, Neurons, Spiro Compounds, Amyloid beta-Protein Precursor, Mice, Exosomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review